And a meta-analysis confirmed that dapagliflozin enhances liver function and glycemic control in patients with T2DM and fatty liver disease, as indicated by reductions in ALT, AST, fasting glucose, and HbA1c [175]. This evidence concerns the gene GPT and type 2 diabetes mellitus.